Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer

For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven approvals within the last 5 years. This accelerated drug development has expanded the reach of targeted therapies, and it may soon be that a majo...

Descripción completa

Detalles Bibliográficos
Autores principales: Vokes, Natalie I., Pan, Kelsey, Le, Xiuning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Controversies in Immunotherapy for Patients with Lung Cancer: Pragmatic Solutions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026098/
https://www.ncbi.nlm.nih.gov/pubmed/36950275
http://dx.doi.org/10.1177/17588359231161409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026098/
https://www.ncbi.nlm.nih.gov/pubmed/36950275
http://dx.doi.org/10.1177/17588359231161409

Ejemplares similares